Compare HSDT & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSDT | OVID |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.1M | 117.5M |
| IPO Year | N/A | 2017 |
| Metric | HSDT | OVID |
|---|---|---|
| Price | $3.31 | $1.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 537.3K | ★ 1.6M |
| Earning Date | 11-18-2025 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $941,000.00 | ★ $6,610,000.00 |
| Revenue This Year | N/A | $1,077.56 |
| Revenue Next Year | $75.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 87.45 | ★ 945.89 |
| 52 Week Low | $2.62 | $0.24 |
| 52 Week High | $1,200.00 | $2.01 |
| Indicator | HSDT | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 46.78 |
| Support Level | $3.07 | $1.57 |
| Resistance Level | $3.65 | $1.65 |
| Average True Range (ATR) | 0.35 | 0.10 |
| MACD | 0.12 | -0.02 |
| Stochastic Oscillator | 64.62 | 5.00 |
Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities. Through this model, Solana Company provides public market investors with efficient and direct exposure to Solana's long-term growth potential.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.